Valid point nzt. Remember some time back a very conservative buy out price based on market activity at that time suggested $300 mil primarily for dog deal was not out of the question. Here we are today with a mc of circa $25-30 mil. Sure other biotechs in similar position however suggest this shows the potential upside for PAA when, as it is likely to do, the markets kick up, especially given additional derisking of the science across various applications. More than the existing holders need to know of the opportunity in order for this to become a chance let alone the reality. Looking forward to learning more about the proposed CEO appointment !
Valid point nzt. Remember some time back a very conservative buy...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |